Roche: immunotherapies show promises in lymphoma
(CercleFinance.com) - Roche said that it was "encouraged" by early results of two new investigational cancer immunotherapies, which may help people with difficult-to-treat lymphomas.
Results showed encouraging efficacy with an objective response rate of 62.7% in slow-growing relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma and 37.1% in aggressive non-Hodgkin lymphoma.
In addition, data demonstrated a complete response rate of 43.3% in slow-growing non-Hodgkin lymphoma and 19.4% in aggressive non-Hodgkin lymphoma.
Copyright (c) 2019 CercleFinance.com. All rights reserved.